Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Director departure
CC transcript
Asset disposition
Quarterly results
ICAGEN INC (ICGN) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/28/2011 8-K Quarterly results
09/22/2011 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
09/06/2011 8-K Changes in Control of Registrant, Financial Statements and Exhibits
08/10/2011 8-K Quarterly results
Docs: "Icagen Reports Second Quarter 2011 Financial Results and Operational Highlights"
07/20/2011 8-K Form 8-K - Current report
06/24/2011 8-K Other Events, Financial Statements and Exhibits
Docs: "Press Release entitled “Icagen Issues Statement in Response to Pfizer SEC Filing” issued by the Company on June 24, 2011"
06/20/2011 8-K Other Events, Financial Statements and Exhibits
Docs: "ICAGEN AND PFIZER INITIATE NAV 1.7 PHASE I MULTIPLE ASCENDING DOSE STUDY , June 20, 2011 - Icagen, Inc. today provided an update on its sodium channel program for pain and related disorders which is being conducted in collaboration with Pfizer. Icagen and Pfizer have initiated a multiple ascending dose study of the lead compound in the collaboration, which targets the ion channel Nav1.7. The objective of this clinical study is to evaluate the safety, tolerability and pharmacokinetics of multiple doses of this novel drug candidate in a placebo controlled study in healthy volunteers. Up to four cohorts of healthy volunteers will receive escalating doses of the drug candidate administered twice a day for a period of fourteen days. P. Kay Wagoner, CEO of Icagen, stated, “We are delighted that,..."
06/06/2011 8-K Form 8-K - Current report
05/04/2011 8-K Quarterly results
Docs: "Icagen Reports First Quarter 2011 Financial Results And Operational Highlights"
04/25/2011 8-K Form 8-K - Current report
03/15/2011 8-K Form 8-K - Current report
03/07/2011 8-K Form 8-K - Current report
02/14/2011 8-K Form 8-K - Current report
02/02/2011 8-K Form 8-K - Current report
01/24/2011 8-K Form 8-K - Current report
01/10/2011 8-K Form 8-K - Current report
12/21/2010 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "ICAGEN ANNOUNCES MANAGEMENT CHANGES",
"ICAGEN AND PFIZER INITIATE PHASE I TRIAL IN NAV1.7 PROGRAM , December 20, 2010 - Icagen, Inc. today provided an update on its sodium channel program for pain and related disorders which is being conducted in collaboration with Pfizer. As previously reported, the companies recently selected a candidate compound to advance into further clinical studies. Dosing of this candidate compound has now been initiated in a Phase I study in healthy volunteers. The safety, tolerability, pharmacokinetics and optimal formulation of the candidate compound will be assessed during a placebo controlled dose escalation in two cohorts of healthy volunteers; exploratory pharmacodynamic end points will be investigated in a third cohort of healthy volunteers. P. Kay Wagoner, CEO of Icagen, stated, “We are delight..."
12/10/2010 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "At Market Issuance Sales Agreement, by and between the Company and McNicoll, Lewis & Vlak LLC",
"Opinion of Wilmer Cutler Pickering Hale and Dorr LLP"
11/30/2010 8-K Form 8-K - Current report
11/09/2010 8-K Quarterly results
Docs: "ICAGEN REPORTS THIRD QUARTER 2010 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS"
10/12/2010 8-K Form 8-K - Current report
10/01/2010 8-K Form 8-K - Current report
09/27/2010 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "ICAGEN ANNOUNCES SECOND RENEWAL OF PFIZER COLLABORATION RESEARCH TRIANGLE PARK, NC, September 23, 2010 - Icagen, Inc. today announced an additional extension through December 2011 to an existing worldwide collaboration and licensing agreement with Pfizer aimed at discovering, developing and commercializing compounds that modify three specific sodium ion channels as new potential treatments for pain and related disorders. For the past three years, Icagen and Pfizer have partnered to identify compounds that target three specific sodium ion channels in a global research and development collaboration overseen by a joint research committee. These sodium channels are important in the generation of electrical signals in nerve fibers that mediate the initiation, transmission and sensation of pain...."
09/21/2010 8-K Form 8-K - Current report
09/14/2010 8-K Form 8-K - Current report
09/03/2010 8-K Other Events, Financial Statements and Exhibits
Docs: "Icagen Sets Date For Reverse Stock Split"
08/10/2010 8-K Form 8-K - Current report
08/03/2010 8-K Other Events
07/30/2010 8-K Form 8-K - Current report
06/29/2010 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "AGTC AND ICAGEN ANNOUNCE TECHNOLOGY TRANSFER AGREEMENT"
06/07/2010 8-K Form 8-K - Current report
05/14/2010 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
05/07/2010 8-K Quarterly results
Docs: "ICAGEN REPORTS FIRST QUARTER 2010 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS"
04/27/2010 8-K Other Events, Financial Statements and Exhibits
Docs: "ICAGEN PROVIDES UPDATE REGARDING CLINICAL DEVELOPMENT PLANS FOR ICA-105665 FDA Approves Icagen's Plan RESEARCH TRIANGLE PARK, NC, April 27, 2010 - Icagen, Inc. today provided an update on clinical development plans for ICA-105665, the Company's novel drug candidate for the treatment of epilepsy and pain. As previously reported, ICA-105665 demonstrated positive results in a recent Phase IIa study in patients with photosensitive epilepsy. At the top dose studied , two of four patients demonstrated a positive response to treatment, as specified by standard pre-defined criteria. In all studies to date, the pharmacokinetics of ICA-105665 suggest twice per day dosing without the need for titration to reach doses which can be tolerated. Based upon the efficacy demonstrated in the recent study of ..."
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy